Vitrolife AB Stock – Fundamental Analysis

Price
98.00
10/14/2026
Jun 2001
Oct 2026

Fundamental Data & Ratios (Balance sheet update: 5/4/2026)

Balance Sheet Total Assets 11,124,000,000.00 ROE 70.96 %
Balance Sheet Total Equity 7,894,000,000.00 ROA -45.06 %
Cashflow Capital Expenditures -175,000,000.00 P/FCF 28.85
Cashflow Free Cash Flow 460,000,000.00 – –
Cashflow Operating Cash Flow 635,000,000.00 P/CF 20.90
Income Earnings per Share (diluted) -37.02 Div. Yield 1.12 %
Income Net Income -5,012,000,000.00 P/E -2.65
Income Shares Outstanding 135,422,600.00 P/B 1.68
Income Total Revenue 3,440,000,000.00 P/S 3.86

Ratios calculated on: 10/14/2026

Company Description

Vitrolife AB (publ), a medical device company, develops, produces, and markets products for assisted reproduction. It offers oocyte retrieval needles; sperm processing; in vitro fertilization media and oil; micromanipulation pipettes; labware; incubators; cryopreservation; and preimplantation genetic testing products. The company also provides EmbryoScope and Primo Vision time-lapse systems; time-lapse dishes; evaluation tools for time-lapse systems; and Octax laser and imaging systems, as well as log and guard systems and wireless sensors. It operates in Europe, the Middle East, and Africa; Asia; Japan and Pacific; and North and South America. The company was formerly known as Scandinavian IVF Science and changed its name to Vitrolife AB (publ) in 1998. Vitrolife AB (publ) was founded in 1994 and is headquartered in Gothenburg, Sweden.

Advanced Analysis Features

Additional comparison and history views are available after login.

Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.vitrolife.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown. Learn more